Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

Figure 2 The forest plot exhibiting pooled effect estimates and indirect comparison between chiglitazar and thiazolidinediones on efficacy endpoints including hemoglobin A1c, fasting blood glucose, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, homeostasis model assessment of insulin resistance, homeostasis model assessment of β cell function, alanine aminotransferase and aspartate aminotransferase. HbA1c: Hemoglobin A1c; FBG: Fasting blood glucose; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; HOMA-IR: Homeostasis model assessment of insulin resistance; HOMA-β: Homeostasis model assessment of β cell function; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; RR: Risk ratios; 95%CI: 95% confidential intervals; TZD: Thiazolidinedione.